Why the study?
Does measuring central blood pressure provide incremental prognostic value beyond peripheral blood pressure in patients with chronic kidney disease?
Does measuring central blood pressure provide incremental prognostic value beyond peripheral blood pressure in patients with chronic kidney disease?
This review highlights the potential of central blood pressure measurement to offer incremental prognostic value for cardiovascular risk in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Central BP measurement should not yet change CKD practice; leaves open its incremental prognostic value beyond peripheral BP.
Chronic kidney disease (CKD) has been consistently associated with cardiovascular disease; there is an inverse graded relationship between glomerular filtration rate and cardiovascular risk. Early-moderate CKD receives increasing recognition for its role as an independent risk factor as evidenced by its recent inclusion in the Joint British Societies' consensus recommendations for the prevention of cardiovascular disease. Data from both imaging and epidemiological studies suggest arterial stiffening and structural left ventricular disease (hypertrophy and fibrosis) are the key pathogenic mediators of cardiovascular disease in CKD. This review discusses the rationale for measuring central blood pressure in patients with CKD and whether it could provide incremental prognostic value beyond that of peripheral blood pressure.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: